Nolan Garry Ph.D.'s Form 4 filing
Akoya Biosciences, Inc. (AKYA) · filed Nov 14, 2022
- Accession no.
- 0001104659-22-118809
- Filed
- Nov 14, 2022
- Trade date
- Nov 10-14, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $324.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nolan Garry Ph.D.CIK 0001857405 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2022 | Common Stock | SSaleDisposed | −3,810 | $13.31 | −$50,711.1 | 618,978 | Direct | |
| Nov 11, 2022 | Common Stock | SSaleDisposed | −20,000 | $13.29 | −$265,800 | 598,978 | Direct | |
| Nov 14, 2022 | Common Stock | SSaleDisposed | −600 | $13.28 | −$7,968 | 598,378 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.